ACADIA PHARMACEUTICALS INC.
Moat Score — ACADIA Pharmaceuticals Inc.
Total Moat Score
15 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 5 / 5 | NUPLAZID and DAYBUE are each the first and only FDA-approved treatment in their respective indications, backed by patent protection and regulatory exclusivity that gives ACADIA a genuine, legally-enforced monopoly position in Parkinson's disease psychosis and Rett syndrome today. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | ACADIA is a mid-size specialty pharma competing against much larger pharmaceutical companies with greater manufacturing and capital resources; its edge is regulatory exclusivity and clinical differentiation rather than production cost. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | As the sole approved therapy in two distinct indications with no direct on-label competitors, ACADIA has demonstrated strong pricing power, though cheap off-label generic antipsychotics constrain NUPLAZID pricing at the margin. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in pharmaceuticals; a patient's clinical benefit from NUPLAZID or DAYBUE is unrelated to how many other patients are prescribed the same drug. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Physicians and patients who have established a treatment regimen face some switching friction from clinical familiarity and treatment continuity, but this is a soft behavioral switching cost rather than a structural one, especially once new competing therapies (such as emerging Rett syndrome gene therapies) become available. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | Both NUPLAZID's and DAYBUE's addressable patient populations are relatively small and specialized, and the clinical development, regulatory, and specialist-sales infrastructure required to serve them profitably limits how many competitors can economically justify entering these narrow indications while ACADIA already holds first-mover position. |